DW 1601
Alternative Names: DW-1601Latest Information Update: 22 Apr 2022
At a glance
- Originator Daewon Pharmaceutical
- Class Antibronchitics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Bronchitis
Most Recent Events
- 22 Apr 2022 No development reported - Phase-III for Bronchitis (In the elderly, In adults) in South Korea (unspecified route)